The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients That Are “Poor Responder” to Induction- The Mayo Clinic Experience

We report the outcomes of 117 newly diagnosed multiple myeloma patients who received novel agents induction, had a poor response to induction and were mobilized using intravenous intermediate-dose cyclophosphamide (82%) or VD-PACE (18%) plus G-CSF and “on-demand” plerixafor. The median PFS and OS of the chemo-mobilized cohort were 21 months (95% CI 15-71) and 58 months (95% CI 47-80), respectively. We compared our cohort to a 117-patient cohort matched by the level of response at pretransplant evaluation.

Source: Biology of Blood and Marrow Transplantation - June 18, 2021 Category: Hematology Authors: Iuliana Vaxman, Eli Muchtar, Eapen Jacob, Kapoor Prashant, Shaji Kumar, Angela Dispenzieri, Francis Buadi, David Dingli, Wilson Gonsalves, Taxiarchis Kourelis, Rahma Warsame, Martha Lacy, William Hogan, Morie Gertz Source Type: research